Inogen Names Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning
May 18 2022 - 4:05PM
Business Wire
Inogen, Inc. (NASDAQ: INGN), a medical technology company
offering innovative respiratory products for use in the homecare
setting, today announced the appointment of Agnes Lee to the
position of Senior Vice President of Investor Relations and
Strategic Planning, effective May 23, 2022.
Nabil Shabshab, President and Chief Executive Officer, said, “I
am excited to welcome Agnes to the Inogen team as we continue to
strengthen our strategic planning capabilities, further execute
against our growth initiatives and communicate our strategy
internally and externally, all with the overarching goal of
transforming Inogen and driving shareholder value. Agnes brings
extensive medical technology and life sciences experience and has
an excellent track record in effective engagement with shareholders
and analysts.”
Agnes joins Inogen from Butterfly Network, where she served as
Vice President of Investor Relations. While at Butterfly, she
created an investor relations program to promote the company to
analysts and investors and collaboratively led investor marketing
to reflect an evolution of the company’s vision and strategy. Prior
to Butterfly, she led proactive investor relations programs at
Fluidigm and ResMed, Inc., playing pivotal roles in communicating
changes in strategy, and global investor marketing. She started her
investor relations career at Life Technologies, which was acquired
by Thermo Fisher Scientific in 2014. Before that role, Agnes spent
almost a decade serving in increasing finance leadership roles at
Life Technologies, Applied Biosystems, and Celera Diagnostics. She
also worked in investment banking earlier in her career. Agnes
holds an MBA in Finance and Marketing from the Kellogg School of
Management at Northwestern University and a BA in Economics and
International Affairs from Indiana University Bloomington.
Agnes commented, “I am thrilled to join Inogen at such an
exciting time in Inogen’s journey. I have been impressed by the
work that Nabil and the rest of the management team have done to
transform Inogen. There is a tremendous opportunity ahead for the
company and I look forward to working with the team to evolve our
long-term strategy and communicate that story to investors.”
About Inogen
Inogen is a medical technology company offering innovative
respiratory products for use in the homecare setting. The Company
primarily develops, manufactures and markets innovative portable
oxygen concentrators used to deliver supplemental long-term oxygen
therapy to patients suffering from chronic respiratory
conditions.
For more information, please visit www.inogen.com.
Inogen has used, and intends to continue to use, its Investor
Relations website, http://investor.inogen.com/, as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD. For more
information, visit http://investor.inogen.com/.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements regarding Inogen’s goals
and potential, statements regarding our continuing to strengthen
our strategic planning capabilities and further execute against our
growth initiatives, and statements regarding our ability to
communicate our strategy internally, and externally, and statements
regarding our goal of transforming Inogen and driving shareholder
value. Any statements contained in this communication that are not
statements of historical fact may be deemed to be forward-looking
statements. Words such as “believes,” “anticipates,” “plans,”
“expects,” “will,” “intends,” “potential,” “possible,” and similar
expressions are intended to identify forward-looking statements.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from currently anticipated results, including but not limited to,
risks related to its announced management and organizational
changes, and risks arising from the possibility that Inogen will
not realize anticipated future financial performance or strategic
goals. In addition, Inogen's business is subject to numerous
additional risks and uncertainties, including, among others, risks
relating to market acceptance of its products; competition; its
sales, marketing and distribution capabilities; its planned sales,
marketing, and research and development activities; interruptions
or delays in the supply of components or materials for, or
manufacturing of, its products; seasonal variations; unanticipated
increases in costs or expenses; and risks associated with
international operations. Information on these and additional
risks, uncertainties, and other information affecting Inogen’s
business operating results are contained in its Annual Report on
Form 10-K for the period ended December 31, 2021 and Inogen’s
Quarterly Report on Form 10-Q for the period ended March 31, 2022,
and in its other filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof. Inogen disclaims any obligation to update these
forward-looking statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220518006021/en/
Investor and Media Contacts Bryan Locke, Mike DeGraff,
Gabriella Coffey ir@inogen.net
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Apr 2023 to Apr 2024